GlassScriptPhysician profile
Patrick L Stoner
NPI 1558724237
$3,075.76
in general payments reported to CMS, 2019-2025
19 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $124 · 2021: $107 · 2022: $61.72 · 2023: $598 · 2024: $1,165 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,509.60 | 2019-2025 | Creon, Linzess, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $257.77 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $214.95 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $195.17 | 2019-2024 | |
| Janssen Biotech, INC. | $164.31 | 2023-2024 | Stelara, Simponi, Remicade |
| Gilead Sciences, INC. | $147.59 | 2020-2025 | Epclusa |
| Celgene Corporation | $112.80 | 2023-2024 | Zeposia |
| Medtronic, INC. | $106.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.26 | 2024-2025 | Entyvio |
| Genzyme Corporation | $57.71 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $51.66 | 2025 | Zenpep |
| Organon LLC | $30.63 | 2024 | |
| Lilly USA, LLC | $23.46 | 2024 | Omvoh |
| Celltrion USA INC. | $21.47 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $21.20 | 2024 | Iqirvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $20.04 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.43 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $15.40 | 2024 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.63 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Stoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.